# US 2025/0152570 A1 · Uses of Selonsertib in the Preparation of Drugs for the Treatment of Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152570 A1
- Document ID: US20250152570A1
- Status: Published application
- Kind: A1
- Application number: 19/019,396
- Filed: 2025-01-13
- Published: 2025-05-15
- Earliest claimed: 2022-12-28
- Assignees: Air Force Medical University
- Applicants: Air Force Medical University
- Inventors: Zhe Wang; Mingyang Li; Jia Chai; Yanru Yang; Jing Ma; Linni Fan; Yixiong Liu; Yao Lv; Junpeng Xu; Tianqi Xu; Shoubin Qian; Shuai He; Jin Liu; Junyang Song; Lingfei Li
- Web page: https://patentgrep.com/patent/US20250152570A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention belongs to the field of medicine and specifically relates to the use of Selonsertib in the preparation of drugs for the treatment of cancer. The Selonsertib is the English name of the compound 5-(4-cyclopropyl-1H-imidazole-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridine-2-yl)-4-methylbenzamide, and its chemical formula is C24H24FN7O, CAS No.: 1448428-04-3. The results of the present invention show that Selonsertib can efficiently inhibit the activity of RSK4 kinase, and has a significant inhibitory effect on the growth of a variety of tumors, and can reduce the resistance of tumors to EGFR-TKI-targeted drugs when combined with EGFR-TKI-targeted drugs. Selonsertib in combination with Anti-PD1 has a significant effect on inhibiting tumor growth compared with the drug alone. The pharmaceutical composition containing Selonsertib provided by the present invention has a good application prospect in the targeted therapy of a variety of cancers.

## Claims

### Claim 1

The use of compound 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide in the preparation of drugs for the treatment of esophageal squamous cell carcinoma is characterized by the fact that the compound 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl) The chemical formula of pyridine-2-yl)-4-methylbenzamide is C24H24FN7O and the structural formula is as follows:

### Claim 2 (depends on 1)

The use of claim 1, wherein the compound 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide combined with EGFR-TKI targeted drug is used to prepare drugs for the treatment of esophageal squamous cell carcinoma, The EGFR-TKI is an epidermal growth factor receptor tyrosine kinase inhibitor.

### Claim 3 (depends on 2)

The use of claim 2, wherein the EGFR-TKI-targeted drug and compound 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridine-2-yl)-4-methylbenzamide are administered continuously at the same time or in any sequence.

### Claim 4 (depends on 3)

The use of claim 3, wherein the drug is used for the treatment of esophageal squamous cell carcinoma that have developed resistance to EGFR-TKI-targeted drugs, or for the prevention and treatment of esophageal squamous cell carcinoma acquired resistance to EGFR-TKI-targeted drugs, or for the prevention and treatment of esophageal squamous cell carcinoma recur after discontinuation of treatment with EGFR-TKI-targeted drugs; the EGFR-TKI-targeted drugs comprises Icotinib or Afatinib.

### Claim 5

The use of compound 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide as the only active ingredient in the preparation of drugs for the treatment of melanoma is characterized by the fact that the compound 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl) The chemical formula of pyridine-2-yl)-4-methylbenzamide is C24H24FN7O and the structural formula is as follows:

### Claim 6 (depends on 5)

The use of claim 5, wherein the compound 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridine-2-yl)-4-methylbenzamide combined with Anti-PD1 is used, and the Anti-PD1 is a humanization IgG4 antibody is an inhibitor of PD-1, the PD-1 is programmed death receptor 1, and Anti-PD1 includes: Pembrolizumab, Nivolumab, Sintilimab, Toripalimab, Camrelizumab.

### Claim 7 (depends on 6)

The use of claim 6, wherein the Anti-PD1 and the compound 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridine-2-yl)-4-methylbenzamide are administered continuously at the same time or in any sequence.
